JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

JNJ

188.98

-0.04%↓

ABT

123.58

-0.84%↓

TMO

568.01

+2.1%↑

ISRG

534.39

+0.84%↑

DHR

215.62

+0.34%↑

Strona główna・Stock List・Ascendis Pharma A-S ADR

Ascendis Pharma A-S ADR

Closed

SectorHealthcare

201.37 -0.95

Buy Sell

Overview

Share price change

24h

Current

Min

200.72

Max

202.46

Key metrics
By Trading Economics
Income	56M -39M
Sales	57M 158M
Profit margin	-24.585
Employees	1,017
EBITDA	51M 2.3M

Recommendations
By TipRanks
Recommendations	Strong Buy
12 Months Forecast	+27.79% upside

Dividends
By Dow Jones
Next Earnings	13 lis 2025

Market Stats
By TradingEconomics
Market Cap	1.2B 12B
Previous open	202.32
Previous close	201.37

News Sentiment

By Acuity

50%

154 / 373 Ranking in Healthcare

Technical Score

By Trading Central

Confidence

Very Strong Bearish Evidence

157.66 / 167.29 Support & Resistance

Ascendis Pharma A-S ADR Chart

Wyniki osiągnięte w przeszłości nie są gwarantem przyszłych wyników.

Related News

31 paź 2025, 17:40 UTC

Acquisitions, Mergers, Takeovers

Orange to Buy Lorca's 50% Stake in MasOrange for $4.9 Billion

1 lis 2025, 12:56 UTC

Earnings

Berkshire's Quarterly Earnings Rise After Insurance Results Improve -- WSJ

1 lis 2025, 12:56 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 lis 2025, 12:20 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 lis 2025, 12:19 UTC

Earnings

Acquisitions, Mergers, Takeovers

Berkshire Operating Profits Rose 33% in Third Quarter. There Were No Stock Buybacks. -- Barrons.com

1 lis 2025, 08:20 UTC

Market Talk

Financial Services Roundup: Market Talk

1 lis 2025, 08:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

1 lis 2025, 00:10 UTC

Earnings

Trouble on The Strip -- Barrons.com

31 paź 2025, 23:09 UTC

Earnings

Review & Preview: October Surprise -- Barrons.com

31 paź 2025, 22:44 UTC

Acquisitions, Mergers, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 paź 2025, 21:25 UTC

Market Talk

Acquisitions, Mergers, Takeovers

Pfizer Says Novo Nordisk's Metsera Bid Won't Pass Antitrust Laws -- Market Talk

31 paź 2025, 21:20 UTC

Acquisitions, Mergers, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- Update

31 paź 2025, 21:12 UTC

Acquisitions, Mergers, Takeovers

Pfizer Sues Metsera, Novo Nordisk, Claiming Novo Nordisk Takeover Offer Isn't Superior -- WSJ

31 paź 2025, 21:12 UTC

Acquisitions, Mergers, Takeovers

Pfizer Sues Seeking to Block Novo Nordisk's Effort to Undo Weight-Loss Drug Deal -- WSJ

31 paź 2025, 21:12 UTC

Acquisitions, Mergers, Takeovers

Pfizer Seeks Order Blocking Metsera From Terminating Its Merger Deal With Pfizer -- WSJ

31 paź 2025, 20:51 UTC

Acquisitions, Mergers, Takeovers

Another Rare-Earth Stock Jumps on Government Deal -- Barrons.com

31 paź 2025, 20:50 UTC

Market Talk

Financial Services Roundup: Market Talk

31 paź 2025, 20:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

31 paź 2025, 20:50 UTC

Market Talk

Earnings

Auto & Transport Roundup: Market Talk

31 paź 2025, 20:46 UTC

Acquisitions, Mergers, Takeovers

Pfizer: Files Lawsuit Against Metsera and Its Directors and Novo Nordisk for Breach of Merger Agreement

31 paź 2025, 20:22 UTC

Earnings

Amazon Stock Hits New Record. What Was So Good in Its Earnings Report. -- Barrons.com

31 paź 2025, 20:02 UTC

Earnings

Meta Faces a Sudden Reckoning. How Big Tech Earnings Are Reshaping the AI Race. -- Barrons.com

31 paź 2025, 19:55 UTC

Market Talk

Crude Futures Fall for Third Straight Month -- Market Talk

31 paź 2025, 19:54 UTC

Acquisitions, Mergers, Takeovers

Pfizer: FTC Granted Early Termination of Waiting Period >PFE

31 paź 2025, 19:54 UTC

Acquisitions, Mergers, Takeovers

Pfizer: Receives Early Clearance From FTC for Metsera Acquisition

31 paź 2025, 19:26 UTC

Market Talk

U.S. Natural Gas Rises on Winter Outlook, Strong LNG -- Market Talk

31 paź 2025, 18:30 UTC

Earnings

These Stocks Are Moving the Most Today: Amazon, Nvidia, Apple, Netflix, Exxon, DexCom, Coinbase, Reddit, Newell Brands, and More -- Barrons.com

31 paź 2025, 18:23 UTC

Market Talk

Gold Edges Lower for the Day, Closes October Positive -- Market Talk

31 paź 2025, 18:09 UTC

Earnings

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

31 paź 2025, 18:08 UTC

Earnings

Bank of America Has a Game Plan to Catch Up to Its Peers. It's Time to Buy the Stock. -- Barrons.com

Peer Comparison

Price change

Ascendis Pharma A-S ADR Forecast

Price Target

By TipRanks

27.79% upside

12 Months Forecast

Average 257.63 USD 27.79%

High 307 USD

Low 220 USD

Based on 16 Wall Street analysts offering 12 month price targets forAscendis Pharma A-S ADR - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

16 ratings

Buy

Hold

Sell

Based on 16 analysts giving stock ratings to Ascendis Pharma A-S ADR - Dist in the past 3 months.

Technical Score

By Trading Central

157.66 / 167.29Support & Resistance

Recent bearish events outweigh bullish events.

Bullish events outweigh bearish events.

All events are bullish.

Sentiment

By Acuity

154 / 373 Ranking in Healthcare

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

About Ascendis Pharma A-S ADR

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.